| Date Filed | Type | Description |
| 07/24/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2023 |
SC 13G/A
| Camber Capital Management LP reports a 9.3% stake in Puma Biotechnology, Inc. |
| 02/02/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 12/12/2022 |
SC 13G
| Camber Capital Management LP reports a 7.3% stake in Solid Biosciences Inc. |
| 08/19/2022 |
SC 13G
| Camber Capital Management LP reports a 8.1% stake in Quanterix Corporation |
| 05/12/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 03/21/2022 |
SC 13G
| Camber Capital Management LP reports a 7.7% stake in ZIMVIE INC. |
| 02/14/2022 |
SC 13G/A
| Camber Capital Management LP reports a 3% stake in Collegium Pharmaceutical, Inc. |
| 02/14/2022 |
SC 13G/A
| Camber Capital Management LP reports a 3.4% stake in Myriad Genetics, Inc. |
| 02/14/2022 |
SC 13G/A
| Camber Capital Management LP reports a 3.7% stake in AVROBIO, INC. |
| 02/14/2022 |
SC 13G/A
| Camber Capital Management LP reports a 5% stake in Puma Biotechnology, Inc. |
| 02/14/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 11/08/2021 |
SC 13D
| Camber Capital Management LP reports a 5.9% stake in ORASURE TECHNOLOGIES, INC |
| 07/29/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/16/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/16/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/16/2021 |
SC 13G/A
| Camber Capital Management LP reports a 4.6% stake in GlycoMimetics, Inc. |
| 02/16/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/16/2021 |
SC 13G/A
| Camber Capital Management LP reports a 6.4% stake in Puma Biotechnology, Inc |
| 02/16/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/16/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 11/30/2020 |
SC 13G
| Camber Capital Management LP reports a 7.6% stake in AVROBIO, INC. |
| 07/13/2020 |
SC 13G
| Camber Capital Management LLC reports a 5.5% stake in Change Healthcare Inc |
| 06/29/2020 |
SC 13G
| Camber Capital Management LLC reports a 6.1% stake in Puma Biotechnology, Inc |
| 06/22/2020 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/21/2020 |
SC 13G
| Camber Capital Management LLC reports a 6% stake in Collegium Pharmaceutical, Inc |
| 02/14/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2020 |
SC 13G/A
| Camber Capital Management LLC reports a 0% stake in Cyclerion Therapeutics, Inc |
| 02/14/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
|